Clinical Trial Update: A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating paritaprevir/ritonavir with ombitasvir, with and without ribavirin, in treatment-naïve patients with genotype 1–3 chronic hepatitis C; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ombitasvir (ombitasvir)
• Paritaprevir (paritaprevir)
• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Hepatitis C Virus | Phase 2 | Status: COMPLETED | Results posted: 2016-07-11